Advances in Research on Human Meningiomas

Guest Editors:

Prof. Dr. Sverre Helge Torp
1. Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
2. Department of Pathology, St. Olavs Hospital, 7006 Trondheim, Norway

Dr. David Scheie
Department of Pathology, Righospitalet, Copenhagen University Hospital. Frederik Vs vej 11, 2100 Copenhagen, Denmark

Deadline for manuscript submissions:
closed (1 July 2021)

Message from the Guest Editors

Dear Colleagues,

This Special Issue deals with human meningiomas, which are mostly benign and slow-growing tumors. Their biology can, however, be capricious as some cases recur despite a benign histology. Thus, the histopathological grading system of these tumors is suboptimal, and more objective diagnostic and prognostic biomarkers are required. For instance, methylation-based tumor classification is highly relevant. For most meningioma patients treated with optimal surgical and radiation approaches, outcomes are good. Unfortunately, some of these tumors cannot be totally resected, and some may recur even after complete resection and radiotherapy. Furthermore, both surgery and radiotherapy may have troublesome and serious complications. Accordingly, this Special Issue welcomes papers on biomarkers that can improve our diagnostic and prognostic work-up of these tumors.

mdpi.com/si/57888

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us